3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
CNS
1
Conditions
Carcinoma, Renal Cell
13
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
von Hippel-Lindau Disease
3
Pheochromocytoma
1
Paraganglioma
1
Kidney Neoplasms
1
Carcinoma
1
Breast Neoplasms
1
Adenoma, Islet Cell
1
Interventions
gallium Ga 68 dotatate
3
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
olaparib
2
lutetium Lu 177 dotatate
2
Fluorodeoxyglucose F18
2
6-fluorodopamine
2
tipifarnib
1
fluorodopa F 18
1
fludarabine phosphate
1
belzutifan
1
Temozolomide
1
Nivolumab
1
Ipilimumab
1
Interleukin-13
1
Cyclophosphamide
1
Contrast Media
1
CTLA-4 Antigen
1
Biopsy
1
3-Iodobenzylguanidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pheochromocytoma
×
belzutifan
×
90 days
×
Clear all
NCT04924075
2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
322 enrolled
1 FDA